Aifen Lin1, Ze-Bao He2, Sheng Zhang3, Jian-Gang Zhang1, Xia Zhang1, Wei-Hua Yan4. 1. Biological Resource Center, Taizhou Hospital of Zhejiang Province, Taizhou Enze Medical Center (Group), Linhai, Zhejiang, China. 2. Department of Infectious Diseases, Enze Hospital, Taizhou Enze Medical Center (Group), Luqiao, Zhejiang, China. 3. Department of Intensive Care Unit, Taizhou Hospital of Zhejiang Province, Taizhou Enze Medical Center (Group), Linhai, Zhejiang, China. 4. Medical Research Center, Taizhou Hospital of Zhejiang Province, Taizhou Enze Medical Center (Group), Linhai, Zhejiang, China.
Abstract
BACKGROUND: Pneumonia coronavirus disease 2019 (COVID-19) has became a pandemic. However, information on early risk factors for the duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral positivity is not yet available. METHODS: In this prospective study, a cohort of 137 patients with confirmed SARS-CoV-2 were enrolled. Clinical information and laboratory data were retrieved from electronic medical records. Viral positivity duration was calculated by the interval from the day of confirmed SARS-CoV-2 positive results to the day SARS-CoV-2 testing showed negative results in these 137 patients with COVID-19. Early risk factors for the duration of SARS-CoV-2 viral positivity were evaluated. RESULTS: The median SARS-CoV-2 viral positivity duration is 12 days (range, 4 to ~45) for this cohort. Cox regression results showed a significantly shorter viral positivity duration was related to younger age (hazard ratio [HR], .658; P = .017); disease not being severe (HR, .653; P = .076); higher lymphocyte (HR, 1.464; P = .033), eosinophil (HR, 1.514; P = .020), and CD8+ T-cell (HR, 1.745; P = .033) counts; and lower IL-6 (HR, .664; P = .036) and IL-10 (HR, .631; P = .021). Multivariate analysis with covariable-adjusted results showed that the CD8+ T-cell count (HR, 2.376; P= .114) was a predominant risk factor for the duration of SARS-CoV-2 viral positivity. CONCLUSIONS: Our findings show early laboratory parameters such as CD8+ T-cell count to be risk factors for the duration of SARS-CoV-2 viral positivity, which has significance in the control and prevention of the disease.
BACKGROUND:Pneumonia coronavirus disease 2019 (COVID-19) has became a pandemic. However, information on early risk factors for the duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral positivity is not yet available. METHODS: In this prospective study, a cohort of 137 patients with confirmed SARS-CoV-2 were enrolled. Clinical information and laboratory data were retrieved from electronic medical records. Viral positivity duration was calculated by the interval from the day of confirmed SARS-CoV-2 positive results to the day SARS-CoV-2 testing showed negative results in these 137 patients with COVID-19. Early risk factors for the duration of SARS-CoV-2 viral positivity were evaluated. RESULTS: The median SARS-CoV-2 viral positivity duration is 12 days (range, 4 to ~45) for this cohort. Cox regression results showed a significantly shorter viral positivity duration was related to younger age (hazard ratio [HR], .658; P = .017); disease not being severe (HR, .653; P = .076); higher lymphocyte (HR, 1.464; P = .033), eosinophil (HR, 1.514; P = .020), and CD8+ T-cell (HR, 1.745; P = .033) counts; and lower IL-6 (HR, .664; P = .036) and IL-10 (HR, .631; P = .021). Multivariate analysis with covariable-adjusted results showed that the CD8+ T-cell count (HR, 2.376; P= .114) was a predominant risk factor for the duration of SARS-CoV-2 viral positivity. CONCLUSIONS: Our findings show early laboratory parameters such as CD8+ T-cell count to be risk factors for the duration of SARS-CoV-2 viral positivity, which has significance in the control and prevention of the disease.
Authors: Se Yoon Park; Soon Gyu Yun; Jeong Won Shin; Bo Young Lee; Hyo-Ju Son; Seungjae Lee; Eunjung Lee; Tae Hyong Kim Journal: Korean J Intern Med Date: 2020-06-19 Impact factor: 2.884
Authors: John H Stone; Matthew J Frigault; Naomi J Serling-Boyd; Ana D Fernandes; Liam Harvey; Andrea S Foulkes; Nora K Horick; Brian C Healy; Ruta Shah; Ana Maria Bensaci; Ann E Woolley; Sarah Nikiforow; Nina Lin; Manish Sagar; Harry Schrager; David S Huckins; Matthew Axelrod; Michael D Pincus; Jorge Fleisher; Chana A Sacks; Michael Dougan; Crystal M North; Yuan-Di Halvorsen; Tara K Thurber; Zeina Dagher; Allison Scherer; Rachel S Wallwork; Arthur Y Kim; Sara Schoenfeld; Pritha Sen; Tomas G Neilan; Cory A Perugino; Sebastian H Unizony; Deborah S Collier; Mark A Matza; Janeth M Yinh; Kathryn A Bowman; Eric Meyerowitz; Amna Zafar; Zsofia D Drobni; Marcy B Bolster; Minna Kohler; Kristin M D'Silva; Jonathan Dau; Megan M Lockwood; Caroline Cubbison; Brittany N Weber; Michael K Mansour Journal: N Engl J Med Date: 2020-10-21 Impact factor: 176.079